Arcturus Therapeutics Files 8-K on Financials
Ticker: ARCT · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1768224
| Field | Detail |
|---|---|
| Company | Arcturus Therapeutics Holdings Inc. (ARCT) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operations, sec-filing
Related Tickers: ARCT
TL;DR
ARCT filed an 8-K detailing financial results and operations. Check the filing for specifics.
AI Summary
Arcturus Therapeutics Holdings Inc. filed an 8-K on March 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial performance and operational status. Specific financial figures and operational details are contained within the full filing.
Why It Matters
This filing provides investors with crucial updates on Arcturus Therapeutics' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant financial and operational updates that may impact a company's stock price, requiring careful investor review.
Key Players & Entities
- Arcturus Therapeutics Holdings Inc. (company) — Registrant
- March 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38942 (identifier) — SEC File Number
- 10628 Science Center Drive, Suite 250 (address) — Principal executive offices
- San Diego, California 92121 (location) — Address of principal executive offices
- (858) 900-2660 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but specific figures are not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on March 7, 2024.
What is the principal executive office address for Arcturus Therapeutics Holdings Inc.?
The principal executive office is located at 10628 Science Center Drive, Suite 250, San Diego, California 92121.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for Arcturus Therapeutics Holdings Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 968 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2024-03-07 16:05:52
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share ARCT The Nasdaq Stock Mar
Filing Documents
- e619328_8k-arct.htm (8-K) — 27KB
- e619328_ex99-1.htm (EX-99.1) — 86KB
- 0001193805-24-000335.txt ( ) — 296KB
- arct-20240307.xsd (EX-101.SCH) — 3KB
- arct-20240307_lab.xml (EX-101.LAB) — 33KB
- arct-20240307_pre.xml (EX-101.PRE) — 22KB
- e619328_8k-arct_htm.xml (XML) — 4KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Conditions. On March 7, 2024, Arcturus Therapeutics Holdings Inc. (the "Company" or "Arcturus") issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company's financial results for the quarter ended December 31, 2023 and providing a corporate update (the "Press Release"). The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company's filings with the Securities and Exchange Commission (the "SEC"), except as shall be expressly set forth by specific reference in any such filing. Cautionary Note Regarding Forward-Looking This Current Report on Form 8-K and the Press Release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this Current Report on Form 8-K and the Press Release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company's pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the likelihood that preclinical or clinical data will be predictive of future clinical results, including that the results from Kostaive (or ARCT-154) will be predictive of results for updated versions of the vaccine, the potential commercial launch of Kostaive, the continued advancement ARCT-032 or its potential as a treatment for any of the CF population, the c
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated March 7, 2024 104 Cover Page to this Current Report on Form 8-K in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: March 7, 2024 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer